Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
Views & Analysis Will pharma get its own Brexit deal? After the Nissan deal, pharma is looking for similar reassurances
Brexit Hard Brexit could hit UK drug supplies - wholesalers Pharma may decide against launching drugs in UK, warns HDA UK.
News UK drug discovery evolving - and facing up to Brexit A new UK report confirms the shift in pharma R&D spending from in-house teams to greater use of outsourcing and in-licensing - but also warns that investment in drug discovery in the co
News Brexit could marginalise UK life sciences - expert Cancer doctor concerned over impact on life sciences R&D.
Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.